Gilead Sciences, Inc. Stock price

Equities

GILD

US3755581036

Pharmaceuticals

Real-time Estimate Cboe BZX 01:59:29 2023-09-29 pm EDT Intraday chart for Gilead Sciences, Inc. 5-day change 1st Jan Change
74.73 USD -0.92% -0.24% -12.84%
Sales 2023 * 26,872 M Sales 2024 * 27,519 M Capitalization 93 974 M
Net income 2023 * 5,763 M Net income 2024 * 6,621 M EV / Sales 2023 *
4,02x
Net Debt 2023 * 14,092 M Net Debt 2024 * 9,430 M EV / Sales 2024 *
3,76x
P/E ratio 2023 *
16,3x
P/E ratio 2024 *
14,0x
Employees -
Yield 2023 *
4,06%
Yield 2024 *
4,24%
Free-Float99.89%
More Fundamentals * Assessed data
Dynamic Chart
GSK lifts growth ambitions for HIV business on long-acting drug RE
Gilead Sciences Gets EU Committee's Positive Opinion on Expanding Veklury's Indication MT
Gilead Sciences, Inc. Announces CHMP of EMA Adopts Positive Opinion to Extend Use of Veklury to Treat COVID-19 in People with Hepatic Impairment CI
Gilead Sciences Says Yescarta Meets Primary Endpoint in Phase 2 Study in Patients With Large B-Cell Lymphoma MT
Kite, A Gilead Company Announces Car T-Cell Therapy Yescarta® Demonstrates High Response Rate and Durable Remission in ALYCANTE Study as Initial Treatment for Transplant Ineligible Patients with Relapsed/Refractory Large B-Cell Lymphoma CI
US FDA approves GSK's bone marrow cancer therapy RE
GILEAD SCIENCES, INC. : Ex-dividend day for FA
Transcript : Gilead Sciences, Inc. Presents at Morgan Stanley 21st Annual Global Healthcare Conference 2023, Sep-12-2023 11:30 AM CI
North American Morning Briefing: Inflation, -2- DJ
Gilead Sciences, Inc.'s Phase 2 EVOKE-02 Study of Trodelvy® (sacituzumab govitecan-hziy) in Combination With KEYTRUDA® (pembrolizumab) Demonstrates Promising Clinical Activity in First-Line Metastatic Non-Small Cell Lung Cancer CI
Equity Markets Close Higher Ahead of Next Week's Inflation Report MT
US Equity Markets End Slightly Higher Ahead of Next Week's Inflation Report MT
S&P 500 closes up slightly ahead of key US inflation data RE
US Equity Markets Mixed As Traders Await Inflation Data MT
Sector Update: Health Care Stocks Slipping Late Friday8 Afternoon MT
More news
1 day-0.17%
1 week+0.20%
Current month-1.39%
1 month-2.10%
3 months-1.00%
6 months-6.85%
Current year-12.15%
More quotes
1 week
74.53
Extreme 74.5301
76.27
1 month
73.25
Extreme 73.25
78.50
Current year
73.25
Extreme 73.25
88.29
1 year
61.45
Extreme 61.445
89.74
3 years
56.56
Extreme 56.56
89.74
5 years
56.56
Extreme 56.56
89.74
10 years
56.56
Extreme 56.56
123.37
More quotes
Managers TitleAgeSince
Chief Executive Officer 58 2019
Director of Finance/CFO 53 2019
Chief Tech/Sci/R&D Officer 60 2019
Members of the board TitleAgeSince
Director/Board Member 52 2020
Chairman 58 2019
Director/Board Member 68 2009
More insiders
Date Price Change Volume
23-09-29 74.83 -0.78% 1 501 887
23-09-28 75.42 -0.17% 3,483,111
23-09-27 75.55 +0.03% 4,442,649
23-09-26 75.53 +0.94% 5,643,933
23-09-25 74.83 -0.24% 3,885,751

Delayed Quote Nasdaq, September 28, 2023 at 04:00 pm EDT

More quotes
Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows: - sale of drugs (98.9%): for the treatment of HIV (50% of net sales), COVID-19 (7.4%), hepatitis C virus (4%), hepatitis B virus (1.4%) and other (37.2%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV); - other (1.3%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products. Net sales are distributed geographically as follows: the United States (70.6%), Europe (17.8%) and other (11.6%).
More about the company
Trading Rating :
Investor Rating :
ESG Refinitiv :
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
29
Last Close Price
75.42USD
Average target price
91.36USD
Spread / Average Target
+21.14%
Consensus
1st Jan change Capi. (M$)
-12.15% 93 974 M $
+3.92% 73 893 M $
-19.19% 121 B $
+0.97% 63 659 M $
+12.15% 133 B $
-4.02% 53 776 M $
+36.73% 50 860 M $
+12.62% 48 629 M $
-6.16% 47 076 M $
+3.11% 145 B $
Other Pharmaceuticals
  1. Markets
  2. Equities
  3. Stock Gilead Sciences, Inc. - Nasdaq
Discover our Free Content to Help You Better Understand the Stock Market.
100% Free Registration
fermer